Abstract: The present invention relates to a conjugate comprising oxyntomodulin, an immunoglobulin Fc region, and non-peptidyl polymer wherein the conjugate being obtainable by covalently linking oxyntomodulin to immunoglobulin Fc region via non-peptidyl polymer, and a pharmaceutical composition for the prevention or treatment of obesity comprising the conjugates. The conjugate comprising oxyntomodulin and the immunoglobulin Fc of the present invention reduces food intake, suppresses gastric emptying, and facilitates lipolysis without side-effects, unlike native oxyntomodulin, and also shows excellent receptor-activating effects and long-term sustainability, compared to native oxyntomodulin. Thus, it can be widely used in the treatment of obesity with safety and efficacy.

Abstract: The present invention relates to an insulin analog conjugate and use thereof.

Abstract: A glucagon derivative, a long-acting conjugate of the glucagon derivative, and a use thereof are disclosed.

Abstract: A glucagon-like peptide-2 (GLP-2) derivative, a conjugate thereof, and a use thereof are disclosed. The GLP-2 derivative or a conjugate thereof are useful in preventing or treating one or more diseases selected from intestinal disease, intestinal injury, or gastrosia. Additionally, a method for preparing a glucagon-like peptide-2 (GLP-2) derivative and a conjugate thereof is disclosed.

Abstract: A method for treating autoimmune and/or inflammatory diseases includes a step of identifying a subject having a gastrointestinal autoimmune/inflammatory disease. A fasting mimicking diet (FMD) is administered to the subject for a first time period.

Abstract: A glucagon-like peptide-2 (GLP-2) derivative, a conjugate thereof, and a use thereof are disclosed. Additionally, a method for preparing a glucagon-like peptide-2 (GLP-2) derivative and a conjugate thereof is disclosed.

Abstract: A physiologically active polypeptide-immunoglobulin Fc fragment conjugate and a method for making the conjugate are disclosed. The conjugate contains a physiologically active polypeptide linked via a non-peptidyl linker to an immunoglobulin Fc fragment having an FcRn-binding region and maintains the intrinsic binding affinity of the immunoglobulin Fc fragment. A method of maintaining the intrinsic binding affinity of the conjugate for FcRn, and a composition containing the conjugate, which maintains the intrinsic binding affinity of the immunoglobulin Fc fragment for FcRn are also disclosed.

Abstract: A conjugate of a physiologically active polypeptide and immunoglobulin Fc with attenuated immune response is disclosed. Also disclosed are a method for preparing the conjugate, a composition for reducing an immune response including the conjugate, and a method for reducing the immune response of the physiologically active polypeptide. A method for maintaining the reduction in the intrinsic binding affinity of the conjugate for an Fc gamma receptor and/or a complement, and a composition including the conjugate are also disclosed.

Abstract: A glucagon-like peptide-2 (GLP-2) derivative, a conjugate thereof, and a use thereof are disclosed. Additionally, a method for preparing a glucagon-like peptide-2 (GLP-2) derivative and a conjugate thereof is disclosed.

Abstract: Provided are a novel derivative of ?-apopicropodophyllin and a method of preparing the same, and more particularly, a compound represented by Formula 1 below, which is a novel derivative of ?-apopicropodophyllin derived from podophyllotoxin, which is an anticancer agent, a method of preparing the same, and a composition for treating cancer, which includes the compound. In Formula 1, R is a C2 to C10 alkyl group, a C2 to C10 alkyl group containing an allyl- or alkyne, a —[CH2]n—C3 to C8 cycloalkyl group, a substituted or unsubstituted —[CH2]n-phenyl group, a substituted or unsubstituted —[CH2]n—C5 to C6 heteroaromatic group, a —C(?O)—C1 to C8 alkyl group, a substituted or unsubstituted —C(?O)—[CH2]n-phenyl group, or a substituted or unsubstituted —C(?O)—[CH2]n—C5 to C6 heteroaromatic group, wherein n is an integer of 0 to 6.

Abstract: A method for alleviating a symptom of multiple sclerosis or other autoimmune or inflammatory disease includes a step of identifying a subject having multiple sclerosis or other autoimmune diseases. A fasting mimicking diet is administered to the subject for a first predetermined time period, the fasting mimicking diet providing less than 50% of the subject's normal caloric intake. A non-fasting diet is administered to the subject for a second time period following the first time period. The non-fasting diet provides the subject greater than 60 percent of the subject's normal caloric intake but a calorie intake necessary for the subject to return to a normal healthy weight.

Abstract: The present invention relates to a novel insulin analog, use thereof, and a method for preparing the analog.

Abstract: According to various embodiments, an electronic device may include at least one sensor, at least one communication circuit, and a processor electrically connected to the at least one sensor and/or the at least one communication circuit, wherein the processor is configured to determine a relay message generation condition associated with a vehicle based at least on data acquired from the at least one sensor and/or the at least one communication circuit, to generate a relay message based at least on the data acquired from the at least one sensor and/or the at least one communication circuit when the relay message generation condition is satisfied based on the determination result, and to transmit the generated relay message to an external vehicle through the at least one communication circuit.

Abstract: A glucagon derivative, a long-acting conjugate of the glucagon derivative, and a use thereof are disclosed.

Abstract: A method for increasing serum half-life of a protein or peptide and decreasing immunogenicity thereof is disclosed. The method includes site-specifically binding a carrier to a protein or peptide. A protein or peptide produced by the method and the uses thereof are disclosed. The conjugate of the physiologically active protein or peptide can significantly decrease immunogenicity in the human body and thus reduce antibody production rate against the protein or peptide. Therefore, the present conjugate has advantages in that a phenomenon of reduced clinical effects of the physiologically active protein or peptide is low, and it can be effectively used in the development of long-acting formulations having a high safety against the immune response.

Abstract: A glucagon derivative, a long-acting conjugate of the glucagon derivative, and a use thereof are disclosed.

Abstract: The present invention relates to therapeutic uses of a triple agonist having activities to all of glucagon, GLP-1, and GIP receptors, and long-acting conjugates thereof for liver disease.

Abstract: Provided are a novel derivative of ?-apopicropodophyllin and a method of preparing the same, and more particularly, a compound represented by Formula 1 below, which is a novel derivative of ?-apopicropodophyllin derived from podophyllotoxin, which is an anticancer agent, a method of preparing the same, and a composition for treating cancer, which includes the compound. In Formula 1, R is a C2 to C10 alkyl group, a C2 to C10 alkyl group containing an allyl- or alkyne, a —[CH2]n—C3 to C8 cycloalkyl group, a substituted or unsubstituted —[CH2]n-phenyl group, a substituted or unsubstituted —[CH2]n—C5 to C6 heteroaromatic group, a —C(?O)—C1 to C8 alkyl group, a substituted or unsubstituted —C(?O)—[CH2]n-phenyl group, or a substituted or unsubstituted —C(?O)—[CH2]n—C5 to C6 heteroaromatic group, wherein n is an integer of 0 to 6.

Abstract: Provided are a combination including glucagon and a compound or substance with therapeutic activity against a metabolic syndrome and a use thereof.

Abstract: A modified IgG4 Fc fragment useful as a drug carrier is disclosed. When coupled to a drug, the resulting drug-IgG4 Fc conjugate can minimize the effector functions of the IgG4 Fc and the chain exchange with in vivo IgG while maintaining in vivo activity and improving in vivo duration of the drug conjugate.